January 8, 2018
Dr. Ruben Niesvizky, Weill Cornell Medicine Myeloma Center Director, and Dr. Kenar Jhaveri, nephrologist and Professor of Medicine in the Division of Kidney Diseases and Hypertension at Hofstra and Northwell Health, published an editorial in the Journal of the American Medical Association (JAMA) addressing the role of using a special form of hemodialysis in myeloma patients with kidney damage.
December 9, 2017
Researchers and physicians at the Weill Cornell Medicine and NewYork-Presbyterian Multiple Myeloma Center presented cutting-edge research at this year’s American Society of Hematology (ASH) Annual Meeting and Exposition, an educational gathering of over 25,000 clinicians and scientists from around the world who are working to conquer blood disease.
October 26, 2017
Since its inception in 2000, the Lymphoma and Myeloma Congress has grown to include attendees from over 40 countries. The Congress is the premier forum on the latest advances in lymphoma, myeloma and related plasma cell disorders. This year, the Congress utilized a dynamic approach that featured clinical controversies, debates, and interesting lectures involving conversations around current treatment regimens as well as promising treatments in the development pipeline.Approximately 1,000...
June 26, 2017
Terry Atkins, Vice President of Marketing and Communications at Extended Stay America gives Karen Pekle, NP the Hotel Keys of Hope 2017 Oncology Nurse of the Year Award Photo courtesy of Extended Stay AmericaKaren Pekle, nurse practitioner at the Weill Cornell Medicine and NewYork-Presbyterian (WCM/NYP) Myeloma Center, was awarded the 2017 Oncology Nurse of the Year Award in Charleston, South Carolina by the Hotel Keys of Hope Program â a joint initiative between Extended Stay America and the...
March 1, 2017
Hundreds of medical oncologists, hematologists and myeloma specialists from around the world converged in New Dehli, India for the 16th International Myeloma Workshop March 1-4, 2017.This bi-annual conference highlights all aspects of multiple myeloma research and care, ranging from developments and discoveries related to the underlying biology driving the multiple myeloma to the most promising new treatment approaches for multiple myeloma. Additionally, research advancements across the entire...
August 8, 2016
We are proud to be supporting the 2016 Leukemia & Lymphoma Society (LLS) Light the Night Event! Because of the commitment of organizations like LLS to fund innovative research projects and connect patients with supportive services, we have made great progress in the fight against multiple myeloma. Learn more about our research and join our team!
July 16, 2016
Dr. Adriana Rossi talks with Healio about how primary care physicians and kidney specialists are becoming better at detecting an abnormal protein in the blood that's closely linked with myeloma. See what she has to say about how this leads to decreased suffering through earlier detection and intervention.
June 8, 2016
In the June issue of Delta Sky Magazine, Dr. Ruben Niesvizky weighs in on the latest progress in multiple myeloma treatment.
June 6, 2016
In myeloma, there are numerous choices for therapy. We recommend treatments based on the risk level of the disease. Patients are divided into two groups, standard risk and high risk. In most centers, risk categorization is an important consideration when deciding the best course of treatment. Assessing risk typically involves the underlying health and age of the patient, the extent of disease, and genetic abnormalities within the cells. The standard system to classify extent or "stage" is...
April 6, 2016
The Myeloma Center in collaboration with Weill Cornell's Monical Guzman, PhD have received a prestigious translational research grant from the Leukemia and Lymphoma Society (LLS) to study the genesis of secondary malignancies in Multiple Myeloma.Multiple Myeloma is characterized by the uncontrolled proliferation of malignant plasma cells. The introduction of novel agents has resulted in improvement in survival. However, long term use of these agents may lead to the development of second primary...
